文献速递疼痛医学

鞘内κ阿片激动剂、钙通道调节剂与P2X受体拮抗剂联合治疗神经病理性疼痛的等辐射分析

Isobolographic Analysis of Drug Combinations With Intrathecal BRL52537 (κ-Opioid Agonist), Pregabalin (Calcium Channel Modulator), AF 353 (P2X3 Receptor Antagonist), and A804598 (P2X7 Receptor Antagonist) in Neuropathic Rats.
PubMed 文献 · Anesth Analg · 2017-01-01

本研究在脊神经结扎(SNL)神经病理性疼痛大鼠模型中,采用等辐射分析法评估鞘内注射BRL52537(κ阿片激动剂)、普瑞巴林(钙通道调节剂)、AF 353(P2X3受体拮抗剂)和A804598(P2X7受体拮抗剂)的相互作用。结果显示BRL52537与普瑞巴林或A804598联用呈协同作用,其他组合呈相加作用,提示联合用药可提高单药疗效。

要点

  • 鞘内BRL52537、普瑞巴林、AF 353和A804598单药均产生抗痛觉超敏效应。
  • BRL52537+普瑞巴林或BRL52537+A804598呈协同作用,其余组合为相加作用。
  • 联合用药可能提高神经病理性疼痛单药治疗疗效。

核心结论

  • 鞘内BRL52537、普瑞巴林、AF 353和A804598联合应用可协同或相加性减轻SNL诱发的痛觉超敏,提示联合用药可能提高单药疗效。

研究设计与样本

  • 研究采用雄性Sprague-Dawley大鼠SNL神经病理性疼痛模型,鞘内给药,用von Frey纤维测定机械刺激反应,采用等辐射分析法评估药物相互作用。
  • 通过实时聚合酶链反应检测naïve、SNL及药物治疗SNL大鼠脊髓或背根神经节中疼痛相关受体的mRNA表达水平。

主要发现

  • 鞘内BRL52537、普瑞巴林、AF 353和A804598在SNL大鼠中均产生抗痛觉超敏效应。
  • 药物联合研究中,鞘内BRL52537与普瑞巴林或A804598共给药呈协同相互作用,其他药物组合呈相加作用。
  • 效力排序为:BRL52537+普瑞巴林 > BRL52537+A804598 > 普瑞巴林+AF 353 > A804598+普瑞巴林 > BRL52537+AF 353 > AF 353+A804598。
  • 实时聚合酶链反应显示P2X3受体和钙通道mRNA表达水平发生改变,而P2X7受体和κ阿片受体表达水平未改变。

临床怎么用

  • 在神经病理性疼痛模型中,鞘内联合BRL52537与普瑞巴林或A804598可能优于单药治疗,但临床转化需进一步验证。

局限性

  • 研究为动物实验,结果不能直接外推至临床患者。
  • 仅评估了机械痛觉超敏,未涉及其他疼痛行为学指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuropathic pain should be treated with drug combinations exhibiting multiple analgesic mechanisms of action because the mechanism of neuropathic pain involves multiple physiological causes and is mediated by multiple pathways. In this study, we defined the pharmacological interaction of BRL52537 (κ-opioid agonist), pregabalin (calcium channel modulator), AF 353 (P2X3 receptor antagonist), and A804598 (P2X7 receptor antagonist). METHODS: Animal models of neuropathic pain were established by spinal nerve ligation (SNL) in male Sprague-Dawley rats, and responses to the mechanical stimulation using von Frey filaments were measured. Drugs were administered by intrathecal route and were examined for antiallodynic effects, and drug interactions were evaluated using isobolographic analysis. The mRNA expression levels of pain-related receptors in each spinal cord or dorsal root ganglion of naïve, SNL, and drug-treated SNL rats were evaluated using real-time polymerase chain reaction. RESULTS: Intrathecal BRL52537, pregabalin, AF 353, and A804598 produced antiallodynic effects in SNL rats. In the drug combination studies, intrathecal coadministration of BRL52537 with pregabalin or A804598 exhibited synergistic interactions, and other drugs combinations showed additivity. The rank order of potency was observed as follows: BRL52537 + pregabalin > BRL52537 + A804598 > pregabalin + AF 353 > A804598 + pregabalin > BRL52537 + AF 353 > AF 353 + A804598. Real-time polymerase chain reaction indicated that alterations of P2X3 receptor and calcium channel mRNA expression levels were observed, while P2X7 receptor and κ-opioid receptor expression levels were not altered. CONCLUSIONS: These results demonstrated that intrathecal combination of BRL52537, pregabalin, AF 353, and A804598 synergistically or additively attenuated allodynia evoked by SNL, which suggests the possibility to improve the efficacy of single-drug administration.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Jung YH, Kim YO, Han JH, et al. Isobolographic Analysis of Drug Combinations With Intrathecal BRL52537 (κ-Opioid Agonist), Pregabalin (Calcium Channel Modulator), AF 353 (P2X3 Receptor Antagonist), and A804598 (P2X7 Receptor Antagonist) in Neuropathic Rats. Anesth Analg. 2017. PMID: 28277328. doi:10.1213/ANE.0000000000001883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。